Axel Bolte - 01 Jul 2025 Form 4 Insider Report for Inozyme Pharma, Inc. (INZY)

Reporting relationship: Director
Issuer ticker: INZY
Reported as of: 01 Jul 2025
Net transaction value: -$1,695,704
SEC form: 4
Accepted by SEC: 03 Jul 2025, 19:07:07 UTC
Prior SEC filing: 20 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Sanjay Subramanian, as attorney-in-fact for Axel Bolte

Key filing fact

Axel Bolte filed Form 4 for Inozyme Pharma, Inc. (INZY) on 03 Jul 2025.

Key facts

This page summarizes Axel Bolte's Form 4 filing for Inozyme Pharma, Inc. (INZY).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 03 Jul 2025, 19:07.

Change

Previous filing in this sequence was filed on 20 May 2025.
Current net transaction value: -$1,695,704.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001579247 Primary reporting owner

Bolte Axel

Relationship: Director
Address: C/O INOZYME PHARMA, INC., 321 SUMMER STREET SUITE 400, BOSTON
Signature: /s/ Sanjay Subramanian, as attorney-in-fact for Axel Bolte
Signature date: 03 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INZY transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value: $1,695,704
Shares: -423,926
Change %: -100%
Price: $4.00
Shares after: 0
Date: 01 Jul 2025
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INZY transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -234,176
Change %: -100%
Price
Shares after: 0
Date: 01 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 234,176
Exercise price: $2.02
Footnotes: F1, F3

INZY transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -159,187
Change %: -100%
Price
Shares after: 0
Date: 01 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 159,187
Exercise price: $2.77
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Axel Bolte is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger")

Footnote F2

Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law.

Footnote F3

Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option.